Scholars Central

Review articlePublished 2017

Progress in Copper Complexes as Anticancer Agents

Authors: Redouane Tabti, Nassera Tounsi, Christian Gaiddon, Embarek Bentouhami, Laurent Désaubry

Medicinal Chemistry

Volume 7 · Issue 5 · Pages 139–143

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The clinical success of cisplatin has stimulated the quest for novel anticancer metallodrugs during the last two decades. A major emphasis has been put on copper due to its selective cytotoxicity toward malignant cells. This selectivity stems from the hypoxic environment of cancer cells that promotes the reduction of Cu(II) to Cu(I), leading a pro-apoptotic oxidative stress. At the current time, two copper complexes have reached clinical assay, which paves the road to the first copper-based anticancer therapeutics.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Medicinal Chemistry.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedicinal Chemistry
  • SubjectChemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Redouane Tabti”
  • BylineArticles whose byline prints “Nassera Tounsi”
  • BylineArticles whose byline prints “Christian Gaiddon”
  • BylineArticles whose byline prints “Embarek Bentouhami”
  • BylineArticles whose byline prints “Laurent Désaubry”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels